42 related articles for article (PubMed ID: 38485187)
1. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates Targeting Tumor-Specific Mucin Glycoepitopes.
Brassard J; Hughes MR; Roskelley CD; McNagny KM
Front Biosci (Landmark Ed); 2022 Nov; 27(11):301. PubMed ID: 36472102
[TBL] [Abstract][Full Text] [Related]
3. Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates.
Mandal A; Shetty J; Tran CA; Olson WC; Mandal M; Ban B; Pires ES; Adair SJ; Bauer TW; Slingluff CL; Herr JC
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485187
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody 7H2.2 binds the C-terminus of the cancer-oocyte antigen SAS1B through the hydrophilic face of a conserved amphipathic helix corresponding to one of only two regions predicted to be ordered.
Legg MSG; Gagnon SML; Powell CJ; Boulanger MJ; Li AJJ; Evans SV
Acta Crystallogr D Struct Biol; 2022 May; 78(Pt 5):623-632. PubMed ID: 35503210
[TBL] [Abstract][Full Text] [Related]
5. From bench to bedside: the history and progress of CAR T cell therapy.
Mitra A; Barua A; Huang L; Ganguly S; Feng Q; He B
Front Immunol; 2023; 14():1188049. PubMed ID: 37256141
[TBL] [Abstract][Full Text] [Related]
6. Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress.
Yao HP; Zhao H; Hudson R; Tong XM; Wang MH
Drug Discov Today; 2021 Aug; 26(8):1857-1874. PubMed ID: 34224904
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates in solid tumors: a look into novel targets.
Criscitiello C; Morganti S; Curigliano G
J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer.
Knapp KA; Pires ES; Adair SJ; Mandal A; Mills AM; Olson WC; Slingluff CL; Parsons JT; Bauer TW; Bullock TN; Herr JC
Oncotarget; 2018 Feb; 9(10):8972-8984. PubMed ID: 29507667
[TBL] [Abstract][Full Text] [Related]
9. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors.
Pires ES; D'Souza RS; Needham MA; Herr AK; Jazaeri AA; Li H; Stoler MH; Anderson-Knapp KL; Thomas T; Mandal A; Gougeon A; Flickinger CJ; Bruns DE; Pollok BA; Herr JC
Oncotarget; 2015 Oct; 6(30):30194-211. PubMed ID: 26327203
[TBL] [Abstract][Full Text] [Related]
10. SAS1B protein [ovastacin] shows temporal and spatial restriction to oocytes in several eutherian orders and initiates translation at the primary to secondary follicle transition.
Pires ES; Hlavin C; Macnamara E; Ishola-Gbenla K; Doerwaldt C; Chamberlain C; Klotz K; Herr AK; Khole A; Chertihin O; Curnow E; Feldman SH; Mandal A; Shetty J; Flickinger C; Herr JC
Dev Dyn; 2013 Dec; 242(12):1405-26. PubMed ID: 24038607
[TBL] [Abstract][Full Text] [Related]
11. Oocyte specific oolemmal SAS1B involved in sperm binding through intra-acrosomal SLLP1 during fertilization.
Sachdev M; Mandal A; Mulders S; Digilio LC; Panneerdoss S; Suryavathi V; Pires E; Klotz KL; Hermens L; Herrero MB; Flickinger CJ; van Duin M; Herr JC
Dev Biol; 2012 Mar; 363(1):40-51. PubMed ID: 22206759
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
